Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
3.210
0.00 (0.00%)
Dec 20, 2024, 4:00 PM EST - Market closed
Arbutus Biopharma Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | -76.7 | -72.85 | -69.46 | -76.25 | -63.75 | -153.72 | Upgrade
|
| Depreciation & Amortization | 1.41 | 1.4 | 1.43 | 1.75 | 1.98 | 2.03 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | -0.02 | - | - | - | 0.02 | Upgrade
|
| Asset Writedown & Restructuring Costs | 0.17 | - | - | - | - | 66.31 | Upgrade
|
| Loss (Gain) From Sale of Investments | -2.83 | -2.2 | -0.05 | 1 | 0.21 | -0.28 | Upgrade
|
| Loss (Gain) on Equity Investments | - | - | - | - | 2.55 | 22.52 | Upgrade
|
| Stock-Based Compensation | 9.08 | 9.3 | 7.18 | 6.42 | 6.16 | 6.8 | Upgrade
|
| Other Operating Activities | -1.83 | -3.34 | -3.7 | -1.39 | 0.98 | -12.46 | Upgrade
|
| Change in Accounts Receivable | 0.56 | -0.42 | -0.45 | 0.41 | -0.11 | 0.23 | Upgrade
|
| Change in Accounts Payable | -2.26 | -5.76 | 5.22 | 1.91 | 1.67 | -3.31 | Upgrade
|
| Change in Unearned Revenue | -1.2 | -10.66 | 22.46 | - | - | - | Upgrade
|
| Change in Other Net Operating Assets | 1.78 | -1.39 | 2.03 | -1.4 | -1.13 | 0.86 | Upgrade
|
| Operating Cash Flow | -71.83 | -85.94 | -35.36 | -67.53 | -51.44 | -71.01 | Upgrade
|
| Capital Expenditures | -0.1 | -1.01 | -0.51 | -0.81 | -0.23 | -0.59 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 0.02 | - | - | - | 0.01 | Upgrade
|
| Investment in Securities | 31.86 | 51.76 | -74.43 | -11.87 | -14.68 | 28.92 | Upgrade
|
| Investing Cash Flow | 31.76 | 50.77 | -74.94 | -12.68 | -14.91 | 28.34 | Upgrade
|
| Issuance of Common Stock | 54.38 | 30.65 | 31.81 | 137.24 | 86.75 | 18.91 | Upgrade
|
| Other Financing Activities | - | - | - | - | - | 18.55 | Upgrade
|
| Financing Cash Flow | 54.38 | 30.65 | 31.81 | 137.24 | 86.75 | 37.46 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0 | 0.03 | -0.02 | 0.01 | 0.06 | 0.07 | Upgrade
|
| Net Cash Flow | 14.32 | -4.49 | -78.51 | 57.03 | 20.45 | -5.14 | Upgrade
|
| Free Cash Flow | -71.92 | -86.94 | -35.87 | -68.34 | -51.67 | -71.6 | Upgrade
|
| Free Cash Flow Margin | -1066.79% | -479.27% | -91.92% | -621.96% | -747.32% | -1191.07% | Upgrade
|
| Free Cash Flow Per Share | -0.40 | -0.52 | -0.24 | -0.64 | -0.68 | -1.25 | Upgrade
|
| Levered Free Cash Flow | -39.81 | -51.58 | -9.73 | -38.42 | -30.17 | -37.68 | Upgrade
|
| Unlevered Free Cash Flow | -39.72 | -51.3 | -8.65 | -36.63 | -27.66 | -36.36 | Upgrade
|
| Change in Net Working Capital | 1.01 | 12.22 | -22.77 | -0.78 | -0.22 | 2.13 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.